Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People who have been diagnosed with pancreatic cancer confirmed by a laboratory test (not the neuroendocrine type)
• People whose pancreatic tumor has been surgically removed, and who have either received additional treatments such as chemotherapy or radiation before or after surgery, or who were not able to or chose not to receive those additional treatments
• People who have at least one of the following: a blood marker called CA 19-9 that is elevated (above 35 U/mL, measured at least 6 weeks after surgery, with a normal bilirubin level), or cancer features found during surgery that suggest a higher risk of return, such as cancer cells found at the edges of the removed tissue or in nearby lymph nodes
• People who have no clear signs of cancer returning or spreading at the time of their first scan after surgery (or within four weeks of an elevated CA 19-9 result)
• People whose blood test results meet certain minimums for white blood cell counts, platelets, red blood cells, and liver enzyme levels (confirm with trial site for specific values)
• People who are well enough to carry out basic daily activities — specifically, those with an ECOG performance score below 3, meaning they are not completely bedridden (confirm with trial site)
• People who have stopped taking other cancer-fighting treatments for a required period of time before the trial begins
• People who are able to swallow and keep down oral medications, if required by the assigned treatment
• People who are not pregnant, not breastfeeding, and willing to use effective contraception during the study and for at least one month after treatment ends — this applies to both female and male participants, with specific requirements for each group (confirm with trial site for full details)
• People whose case has been reviewed by a Molecular Tumor Board (a specialist panel) and who agree to follow the treatment that panel recommends
• People who are able to understand and are willing to sign a written consent form

Who may not be able to join:

• People whose body does not naturally produce the CA 19-9 marker, unless they have high-risk surgical findings (such as cancer at the surgical margins or in lymph nodes)
• People who are currently taking another experimental treatment for pancreatic cancer
• People whose scans show that the cancer has already spread to other parts of the body
• People who are unable to swallow medications
• People who are having more than 6 episodes of diarrhea per day after surgery, even with maximum medical treatment
• People who have an active infection (bacterial, viral, or fungal) that currently requires intravenous (IV) antibiotic or antifungal treatment
• People who have had a major surgical procedure (other than a simple diagnostic biopsy) within four weeks before the trial start date, or who have a major surgery planned in that window
• People who have a known allergy or sensitivity to any of the study drugs or their ingredients
• People with serious uncontrolled health conditions, such as unstable chest pain (angina), a significant uncontrolled heart rhythm problem, or mental health or personal circumstances that would make it difficult to follow the trial requirements
• People who are pregnant, breastfeeding, or of childbearing potential and not using adequate contraception

Important: Always verify eligibility with the trial site directly before applying.